Antagonists Of The PD-1/PD-L1 Axis In Head And Neck Cancer Treatment:Current Status And Future Directions

Head and neck cancer(HNC)is a common malignant tumor,but traditional therapeutic methods have unsatisfactory curative effects and many complications occur.Hence,there is an urgent need to develop therapeutic methods that can elicit curative effects as well as low toxic and few side effects.With the development of cancer molecular biology and immunology,targeted therapy for immune checkpoints of programmed cell death 1(PD-1)and programmed cell death ligand 1(PD-L1)has shown enormous development prospects for HNC treatment.Groundbreaking progress has been achieved in the treatment of recurrent/metastatic head and neck squamous cell carcinoma(HNSCC).This review describes current treatment by PD-1-and PD-L1-targeted drugs for HNC.